BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Oraya Therapeutics INTREPID Study Demonstrates Two-Year Safety and Effectiveness of Non-Invasive Therapy for Wet AMD


9/25/2013 9:42:50 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEWARK, Calif.--(BUSINESS WIRE)--Oraya® Therapeutics, Inc. announced today the two-year results of its INTREPID study of Oraya Therapy™ Stereotactic Radiotherapy for the treatment of wet age-related macular degeneration (AMD). These results provide continued evidence of a favorable safety profile and the therapy’s ability to reduce the frequency of anti-vascular endothelial growth factor (VEGF) injections in the eye. The broadly inclusive cohort of non-naïve wet AMD patients continued to receive the benefit of a 25 percent mean reduction in anti-VEGF injections over two years. Patients identified in the first year as ideal response candidates maintained an impressive 45 percent mean reduction in anti-VEGF injections through the two-year visit, with superior vision to the non-treated group. In addition, the overall safety profile was positive, with only one percent of treated patients showing evidence of micro-vascular abnormalities due to radiation that could affect vision outcomes.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES